Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 38 entries
Sorted by: Best Match Show Resources per page
Antioxidant Tocols as Radiation Countermeasures (Challenges to be Addressed to Use Tocols as Radiation Countermeasures in Humans).

Antioxidants (Basel, Switzerland)

Nukala U, Thakkar S, Krager KJ, Breen PJ, Compadre CM, Aykin-Burns N.
PMID: 29473853
Antioxidants (Basel). 2018 Feb 23;7(2). doi: 10.3390/antiox7020033.

Radiation countermeasures fall under three categories, radiation protectors, radiation mitigators, and radiation therapeutics. Radiation protectors are agents that are administered before radiation exposure to protect from radiation-induced injuries by numerous mechanisms, including scavenging free radicals that are generated by...

Cite
Nukala U, Thakkar S, Krager KJ, et al. Antioxidant Tocols as Radiation Countermeasures (Challenges to be Addressed to Use Tocols as Radiation Countermeasures in Humans). Antioxidants (Basel). 2018;7(2)doi: 10.3390/antiox7020033.
Nukala, U., Thakkar, S., Krager, K. J., Breen, P. J., Compadre, C. M., & Aykin-Burns, N. (2018). Antioxidant Tocols as Radiation Countermeasures (Challenges to be Addressed to Use Tocols as Radiation Countermeasures in Humans). Antioxidants (Basel, Switzerland), 7(2), . https://doi.org/10.3390/antiox7020033
Nukala, Ujwani, et al. "Antioxidant Tocols as Radiation Countermeasures (Challenges to be Addressed to Use Tocols as Radiation Countermeasures in Humans)." Antioxidants (Basel, Switzerland) vol. 7,2 (2018). doi: https://doi.org/10.3390/antiox7020033
Nukala U, Thakkar S, Krager KJ, Breen PJ, Compadre CM, Aykin-Burns N. Antioxidant Tocols as Radiation Countermeasures (Challenges to be Addressed to Use Tocols as Radiation Countermeasures in Humans). Antioxidants (Basel). 2018 Feb 23;7(2). doi: 10.3390/antiox7020033. PMID: 29473853; PMCID: PMC5836023.
Copy Download .nbib Format: NLM
Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status.

Haematologica

Baker D, Bimali M, Carrillo L, Sachedina A, Alapat D, Hoque MS, Kottarathara M, Parikh R, Erra A, Mitma AA, Mathur P, Ogunsesan Y, Yarlagadda L, Gundarlapalli S, Thanendrarajan S, Zangari M, Van Rhee F, Tricot G, Schinke C.
PMID: 34382384
Haematologica. 2021 Aug 12; doi: 10.3324/haematol.278779. Epub 2021 Aug 12.

Not available.

Cite
Baker D, Bimali M, Carrillo L, et al. Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica. 2021;doi: 10.3324/haematol.278779.
Baker, D., Bimali, M., Carrillo, L., Sachedina, A., Alapat, D., Hoque, M. S., Kottarathara, M., Parikh, R., Erra, A., Mitma, A. A., Mathur, P., Ogunsesan, Y., Yarlagadda, L., Gundarlapalli, S., Thanendrarajan, S., Zangari, M., Van Rhee, F., Tricot, G., & Schinke, C. (2021). Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica, . https://doi.org/10.3324/haematol.278779
Baker, David, et al. "Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status." Haematologica vol. (2021). doi: https://doi.org/10.3324/haematol.278779
Baker D, Bimali M, Carrillo L, Sachedina A, Alapat D, Hoque MS, Kottarathara M, Parikh R, Erra A, Mitma AA, Mathur P, Ogunsesan Y, Yarlagadda L, Gundarlapalli S, Thanendrarajan S, Zangari M, Van Rhee F, Tricot G, Schinke C. Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica. 2021 Aug 12; doi: 10.3324/haematol.278779. Epub 2021 Aug 12. PMID: 34382384.
Copy Download .nbib Format: NLM
Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status.

Haematologica

Baker D, Bimali M, Carrillo L, Sachedina A, Alapat D, Hoque MS, Kottarathara M, Parikh R, Erra A, Mitma AA, Mathur P, Ogunsesan Y, Yarlagadda L, Gundarlapalli S, Thanendrarajan S, Zangari M, Van Rhee F, Tricot G, Schinke C.
PMID: 34847659
Haematologica. 2021 Dec 01;106(12):3215-3218. doi: 10.3324/haematol.2021.278779.

No abstract available.

Cite
Baker D, Bimali M, Carrillo L, et al. Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica. 2021;106(12):3215-3218doi: 10.3324/haematol.2021.278779.
Baker, D., Bimali, M., Carrillo, L., Sachedina, A., Alapat, D., Hoque, M. S., Kottarathara, M., Parikh, R., Erra, A., Mitma, A. A., Mathur, P., Ogunsesan, Y., Yarlagadda, L., Gundarlapalli, S., Thanendrarajan, S., Zangari, M., Van Rhee, F., Tricot, G., & Schinke, C. (2021). Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica, 106(12), 3215-3218. https://doi.org/10.3324/haematol.2021.278779
Baker, David, et al. "Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status." Haematologica vol. 106,12 (2021): 3215-3218. doi: https://doi.org/10.3324/haematol.2021.278779
Baker D, Bimali M, Carrillo L, Sachedina A, Alapat D, Hoque MS, Kottarathara M, Parikh R, Erra A, Mitma AA, Mathur P, Ogunsesan Y, Yarlagadda L, Gundarlapalli S, Thanendrarajan S, Zangari M, Van Rhee F, Tricot G, Schinke C. Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status. Haematologica. 2021 Dec 01;106(12):3215-3218. doi: 10.3324/haematol.2021.278779. PMID: 34847659; PMCID: PMC8634177.
Copy Download .nbib Format: NLM
Cognitive impairment resulting from treatment with docetaxel, doxorubicin, and cyclophosphamide.

Brain research

Brown T, McElroy T, Simmons P, Walters H, Ntagwabira F, Wang J, Byrum SD, Allen AR.
PMID: 33705788
Brain Res. 2021 Jun 01;1760:147397. doi: 10.1016/j.brainres.2021.147397. Epub 2021 Mar 08.

Breast cancer is the most commonly diagnosed cancer among women and it is estimated that about 30% of newly diagnosed cancers in women will be breast cancers. While advancements in treating breast cancer have led to an average 5-year...

Cite
Brown T, McElroy T, Simmons P, et al. Cognitive impairment resulting from treatment with docetaxel, doxorubicin, and cyclophosphamide. Brain Res. 2021;1760:147397doi: 10.1016/j.brainres.2021.147397.
Brown, T., McElroy, T., Simmons, P., Walters, H., Ntagwabira, F., Wang, J., Byrum, S. D., & Allen, A. R. (2021). Cognitive impairment resulting from treatment with docetaxel, doxorubicin, and cyclophosphamide. Brain research, 1760147397. https://doi.org/10.1016/j.brainres.2021.147397
Brown, Taurean, et al. "Cognitive impairment resulting from treatment with docetaxel, doxorubicin, and cyclophosphamide." Brain research vol. 1760 (2021): 147397. doi: https://doi.org/10.1016/j.brainres.2021.147397
Brown T, McElroy T, Simmons P, Walters H, Ntagwabira F, Wang J, Byrum SD, Allen AR. Cognitive impairment resulting from treatment with docetaxel, doxorubicin, and cyclophosphamide. Brain Res. 2021 Jun 01;1760:147397. doi: 10.1016/j.brainres.2021.147397. Epub 2021 Mar 08. PMID: 33705788.
Copy Download .nbib Format: NLM
Implications of Breast Cancer Chemotherapy-Induced Inflammation on the Gut, Liver, and Central Nervous System.

Biomedicines

Brown T, Sykes D, Allen AR.
PMID: 33668580
Biomedicines. 2021 Feb 13;9(2). doi: 10.3390/biomedicines9020189.

Breast Cancer is still one of the most common cancers today; however, with advancements in diagnostic and treatment methods, the mortality and survivorship of patients continues to decrease and increase, respectively. Commonly used treatments today consist of drug combinations,...

Cite
Brown T, Sykes D, Allen AR. Implications of Breast Cancer Chemotherapy-Induced Inflammation on the Gut, Liver, and Central Nervous System. Biomedicines. 2021;9(2)doi: 10.3390/biomedicines9020189.
Brown, T., Sykes, D., & Allen, A. R. (2021). Implications of Breast Cancer Chemotherapy-Induced Inflammation on the Gut, Liver, and Central Nervous System. Biomedicines, 9(2), . https://doi.org/10.3390/biomedicines9020189
Brown, Taurean, et al. "Implications of Breast Cancer Chemotherapy-Induced Inflammation on the Gut, Liver, and Central Nervous System." Biomedicines vol. 9,2 (2021). doi: https://doi.org/10.3390/biomedicines9020189
Brown T, Sykes D, Allen AR. Implications of Breast Cancer Chemotherapy-Induced Inflammation on the Gut, Liver, and Central Nervous System. Biomedicines. 2021 Feb 13;9(2). doi: 10.3390/biomedicines9020189. PMID: 33668580; PMCID: PMC7917715.
Copy Download .nbib Format: NLM
Effects of intratracheally instilled laser printer-emitted engineered nanoparticles in a mouse model: A case study of toxicological implications from nanomaterials released during consumer use.

NanoImpact

Pirela SV, Lu X, Miousse I, Sisler JD, Qian Y, Guo N, Koturbash I, Castranova V, Thomas T, Godleski J, Demokritou P.
PMID: 26989787
NanoImpact. 2016 Jan;1:1-8. doi: 10.1016/j.impact.2015.12.001. Epub 2016 Jan 21.

Incorporation of engineered nanomaterials (ENMs) into toners used in laser printers has led to countless quality and performance improvements. However, the release of ENMs during printing (consumer use) has raised concerns about their potential adverse health effects. The aim...

Cite
Pirela SV, Lu X, Miousse I, et al. Effects of intratracheally instilled laser printer-emitted engineered nanoparticles in a mouse model: A case study of toxicological implications from nanomaterials released during consumer use. NanoImpact. 2016;1:1-8doi: 10.1016/j.impact.2015.12.001.
Pirela, S. V., Lu, X., Miousse, I., Sisler, J. D., Qian, Y., Guo, N., Koturbash, I., Castranova, V., Thomas, T., Godleski, J., & Demokritou, P. (2016). Effects of intratracheally instilled laser printer-emitted engineered nanoparticles in a mouse model: A case study of toxicological implications from nanomaterials released during consumer use. NanoImpact, 11-8. https://doi.org/10.1016/j.impact.2015.12.001
Pirela, Sandra V, et al. "Effects of intratracheally instilled laser printer-emitted engineered nanoparticles in a mouse model: A case study of toxicological implications from nanomaterials released during consumer use." NanoImpact vol. 1 (2016): 1-8. doi: https://doi.org/10.1016/j.impact.2015.12.001
Pirela SV, Lu X, Miousse I, Sisler JD, Qian Y, Guo N, Koturbash I, Castranova V, Thomas T, Godleski J, Demokritou P. Effects of intratracheally instilled laser printer-emitted engineered nanoparticles in a mouse model: A case study of toxicological implications from nanomaterials released during consumer use. NanoImpact. 2016 Jan;1:1-8. doi: 10.1016/j.impact.2015.12.001. Epub 2016 Jan 21. PMID: 26989787; PMCID: PMC4791579.
Copy Download .nbib Format: NLM
Particle Beam may have Higher Effectiveness in Treating Chemo-resistant Cancers than Low-LET Photon Beam Therapy.

Research & reviews. Journal of pharmacy and pharmaceutical sciences

Pathak R, Hauer-Jensen M.
PMID: 26779544
Res Rev J Pharm Pharm Sci. 2015 Apr-Jun;4(2):1-2. Epub 2015 Jun 14.

No abstract available.

Cite
Pathak R, Hauer-Jensen M. Particle Beam may have Higher Effectiveness in Treating Chemo-resistant Cancers than Low-LET Photon Beam Therapy. Res Rev J Pharm Pharm Sci. 2015;4(2):1-2
Pathak, R., & Hauer-Jensen, M. (2015). Particle Beam may have Higher Effectiveness in Treating Chemo-resistant Cancers than Low-LET Photon Beam Therapy. Research & reviews. Journal of pharmacy and pharmaceutical sciences, 4(2), 1-2.
Pathak, Rupak, and Hauer-Jensen, Martin. "Particle Beam may have Higher Effectiveness in Treating Chemo-resistant Cancers than Low-LET Photon Beam Therapy." Research & reviews. Journal of pharmacy and pharmaceutical sciences vol. 4,2 (2015): 1-2.
Pathak R, Hauer-Jensen M. Particle Beam may have Higher Effectiveness in Treating Chemo-resistant Cancers than Low-LET Photon Beam Therapy. Res Rev J Pharm Pharm Sci. 2015 Apr-Jun;4(2):1-2. Epub 2015 Jun 14. PMID: 26779544; PMCID: PMC4712956.
Copy Download .nbib Format: NLM
Study of Image Qualities From 6D Robot-Based CBCT Imaging System of Small Animal Irradiator.

Technology in cancer research & treatment

Sharma S, Narayanasamy G, Clarkson R, Chao M, Moros EG, Zhang X, Yan Y, Boerma M, Paudel N, Morrill S, Corry P, Griffin RJ.
PMID: 28355964
Technol Cancer Res Treat. 2017 Dec;16(6):811-818. doi: 10.1177/1533034617700558. Epub 2017 Mar 30.

PURPOSE: To assess the quality of cone beam computed tomography images obtained by a robotic arm-based and image-guided small animal conformal radiation therapy device.METHOD AND MATERIALS: The small animal conformal radiation therapy device is equipped with a 40 to...

Cite
Sharma S, Narayanasamy G, Clarkson R, et al. Study of Image Qualities From 6D Robot-Based CBCT Imaging System of Small Animal Irradiator. Technol Cancer Res Treat. 2017;16(6):811-818doi: 10.1177/1533034617700558.
Sharma, S., Narayanasamy, G., Clarkson, R., Chao, M., Moros, E. G., Zhang, X., Yan, Y., Boerma, M., Paudel, N., Morrill, S., Corry, P., & Griffin, R. J. (2017). Study of Image Qualities From 6D Robot-Based CBCT Imaging System of Small Animal Irradiator. Technology in cancer research & treatment, 16(6), 811-818. https://doi.org/10.1177/1533034617700558
Sharma, Sunil, et al. "Study of Image Qualities From 6D Robot-Based CBCT Imaging System of Small Animal Irradiator." Technology in cancer research & treatment vol. 16,6 (2017): 811-818. doi: https://doi.org/10.1177/1533034617700558
Sharma S, Narayanasamy G, Clarkson R, Chao M, Moros EG, Zhang X, Yan Y, Boerma M, Paudel N, Morrill S, Corry P, Griffin RJ. Study of Image Qualities From 6D Robot-Based CBCT Imaging System of Small Animal Irradiator. Technol Cancer Res Treat. 2017 Dec;16(6):811-818. doi: 10.1177/1533034617700558. Epub 2017 Mar 30. PMID: 28355964; PMCID: PMC5762036.
Copy Download .nbib Format: NLM
A Quantitative Proteomic Analysis of Urine from Gamma-Irradiated Non-Human Primates.

Journal of proteomics & bioinformatics

Byrum SD, Burdine MS, Orr L, Moreland L, Mackintosh SG, Authier S, Pouliot M, Hauer-Jensen M, Tackett AJ.
PMID: 26962295
J Proteomics Bioinform. 2016;9. doi: 10.4172/jpb.S10-005. Epub 2015 Dec 28.

The molecular effects of total body gamma-irradiation exposure are of critical importance as large populations of people could be exposed either by terrorists, nuclear blast, or medical therapy. In this study, we aimed to identify changes in the urine...

Cite
Byrum SD, Burdine MS, Orr L, et al. A Quantitative Proteomic Analysis of Urine from Gamma-Irradiated Non-Human Primates. J Proteomics Bioinform. 2015;9doi: 10.4172/jpb.S10-005.
Byrum, S. D., Burdine, M. S., Orr, L., Moreland, L., Mackintosh, S. G., Authier, S., Pouliot, M., Hauer-Jensen, M., & Tackett, A. J. (2016). A Quantitative Proteomic Analysis of Urine from Gamma-Irradiated Non-Human Primates. Journal of proteomics & bioinformatics, 9. https://doi.org/10.4172/jpb.S10-005
Byrum, Stephanie D, et al. "A Quantitative Proteomic Analysis of Urine from Gamma-Irradiated Non-Human Primates." Journal of proteomics & bioinformatics vol. 9 (2016). doi: https://doi.org/10.4172/jpb.S10-005
Byrum SD, Burdine MS, Orr L, Moreland L, Mackintosh SG, Authier S, Pouliot M, Hauer-Jensen M, Tackett AJ. A Quantitative Proteomic Analysis of Urine from Gamma-Irradiated Non-Human Primates. J Proteomics Bioinform. 2016;9. doi: 10.4172/jpb.S10-005. Epub 2015 Dec 28. PMID: 26962295; PMCID: PMC4780756.
Copy Download .nbib Format: NLM
Selective, C-3 Friedel-Crafts acylation to generate functionally diverse, acetylated Imidazo[1,2-.

Tetrahedron

Frett B, McConnell N, Kharbanda A, Naresh G, Rounseville B, Warner C, Chang J, Debolske N, Li HY.
PMID: 30344351
Tetrahedron. 2018 Aug 30;74(35):4592-4600. doi: 10.1016/j.tet.2018.07.027. Epub 2018 Jul 17.

Carbon-carbon bonds are integral for pharmaceutical discovery and development. Frequently, C-C bond reactions utilize expensive catalyst/ligand combinations and/or are low yielding, which can increase time and expenditures in pharmaceutical development. To enhance C-C bond formation protocols, we developed a...

Cite
Frett B, McConnell N, Kharbanda A, et al. Selective, C-3 Friedel-Crafts acylation to generate functionally diverse, acetylated Imidazo[1,2-. Tetrahedron. 2018;74(35):4592-4600doi: 10.1016/j.tet.2018.07.027.
Frett, B., McConnell, N., Kharbanda, A., Naresh, G., Rounseville, B., Warner, C., Chang, J., Debolske, N., & Li, H. Y. (2018). Selective, C-3 Friedel-Crafts acylation to generate functionally diverse, acetylated Imidazo[1,2-. Tetrahedron, 74(35), 4592-4600. https://doi.org/10.1016/j.tet.2018.07.027
Frett, Brendan, et al. "Selective, C-3 Friedel-Crafts acylation to generate functionally diverse, acetylated Imidazo[1,2-." Tetrahedron vol. 74,35 (2018): 4592-4600. doi: https://doi.org/10.1016/j.tet.2018.07.027
Frett B, McConnell N, Kharbanda A, Naresh G, Rounseville B, Warner C, Chang J, Debolske N, Li HY. Selective, C-3 Friedel-Crafts acylation to generate functionally diverse, acetylated Imidazo[1,2-. Tetrahedron. 2018 Aug 30;74(35):4592-4600. doi: 10.1016/j.tet.2018.07.027. Epub 2018 Jul 17. PMID: 30344351; PMCID: PMC6192254.
Copy Download .nbib Format: NLM
A Bibliometric Review of Publications on Oxidative Stress and Chemobrain: 1990-2019.

Antioxidants (Basel, Switzerland)

McElroy T, Allen AR.
PMID: 32443630
Antioxidants (Basel). 2020 May 18;9(5). doi: 10.3390/antiox9050439.

Oxidative stress is considered one of the possible mechanisms behind chemobrain or the cognitive dysfunction persistent after chemotherapy treatment. Breast cancer patients have reported chemobrain symptoms since the 1990s. In this present bibliometric review, we employed the VOSviewer tool...

Cite
McElroy T, Allen AR. A Bibliometric Review of Publications on Oxidative Stress and Chemobrain: 1990-2019. Antioxidants (Basel). 2020;9(5)doi: 10.3390/antiox9050439.
McElroy, T., & Allen, A. R. (2020). A Bibliometric Review of Publications on Oxidative Stress and Chemobrain: 1990-2019. Antioxidants (Basel, Switzerland), 9(5), . https://doi.org/10.3390/antiox9050439
McElroy, Taylor, and Allen, Antiño R. "A Bibliometric Review of Publications on Oxidative Stress and Chemobrain: 1990-2019." Antioxidants (Basel, Switzerland) vol. 9,5 (2020). doi: https://doi.org/10.3390/antiox9050439
McElroy T, Allen AR. A Bibliometric Review of Publications on Oxidative Stress and Chemobrain: 1990-2019. Antioxidants (Basel). 2020 May 18;9(5). doi: 10.3390/antiox9050439. PMID: 32443630; PMCID: PMC7278845.
Copy Download .nbib Format: NLM
Synthesis of 4,4'-(4-Formyl-1.

Antibiotics (Basel, Switzerland)

Delancey E, Allison D, Kc HR, Gilmore DF, Fite T, Basnakian AG, Alam MA.
PMID: 32998384
Antibiotics (Basel). 2020 Sep 28;9(10). doi: 10.3390/antibiotics9100650.

No abstract available.

Cite
Delancey E, Allison D, Kc HR, et al. Synthesis of 4,4'-(4-Formyl-1. Antibiotics (Basel). 2020;9(10)doi: 10.3390/antibiotics9100650.
Delancey, E., Allison, D., Kc, H. R., Gilmore, D. F., Fite, T., Basnakian, A. G., & Alam, M. A. (2020). Synthesis of 4,4'-(4-Formyl-1. Antibiotics (Basel, Switzerland), 9(10), . https://doi.org/10.3390/antibiotics9100650
Delancey, Evan, et al. "Synthesis of 4,4'-(4-Formyl-1." Antibiotics (Basel, Switzerland) vol. 9,10 (2020). doi: https://doi.org/10.3390/antibiotics9100650
Delancey E, Allison D, Kc HR, Gilmore DF, Fite T, Basnakian AG, Alam MA. Synthesis of 4,4'-(4-Formyl-1. Antibiotics (Basel). 2020 Sep 28;9(10). doi: 10.3390/antibiotics9100650. PMID: 32998384; PMCID: PMC7601628.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 38 entries